the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid..

.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018...

another new drug in the migraine pipeline is lasmiditan. it works the same way as triptans. but unlike the triptans, it doesn't constrict